Switch from triple to dual therapy
Switch from triple to dual therapy has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 26, 2026: “Time course of onset and offset of blood pressure reduction with a novel low-dose triple single pill combination”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1
“During the ACT randomized period, the withdrawal of one component increased SBP in all arms by week 6”
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave switch from triple to dual therapy to people and measured what changed.
up: Increases systolic blood pressureIncrease within 2 weeks after telmisartan or indapamide withdrawal; more gradual increase over 6 weeks after amlodipine withdrawal.
Randomized trial3,299 peopleadults6 weeks
Hypertension; switching from GMRx2 half dose to corresponding dual half-dose combinations
ESC Congress 2026 abstract, Oct 26, 2026
What did studies of Switch from triple to dual therapy find?
1Studies of Switch from triple to dual therapy measured 1 outcome; the most studied are systolic blood pressure (1 study).
Systolic blood pressure
upin humans1
1 study
Systolic blood pressure
upin humans1
Switch from triple to dual therapy increases systolic blood pressure in humans (hypertension; switching from GMRx2 half dose to corresponding dual half-dose combinations) (Increase within 2 weeks after telmisartan or indapamide withdrawal; more gradual increase over 6 weeks after amlodipine withdrawal.).
“During the ACT randomized period, the withdrawal of one component increased SBP in all arms by week 6”
Human trialhypertension; switching from GMRx2 half dose to corresponding dual half-dose combinations6 weeks
ESC Congress 2026 abstract